Paris, France

Marcel Hollenstein

This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique, Dna Script, Institut Pasteur. Active years: 2024.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marcel Hollenstein: Innovator in Nucleoside Chemistry

Introduction

Marcel Hollenstein is a notable inventor based in Paris, France. He has made significant contributions to the field of nucleoside chemistry, particularly through his innovative methods and techniques. His work has implications for various applications in biochemistry and molecular biology.

Latest Patents

Hollenstein holds a patent for a method titled "Method for preparing 3'-O-amino-2′-deoxyribonucleoside-5′-triphosphate." This invention relates to a method for preparing 3'-O-amino-2′-deoxyribonucleoside-5′-triphosphate. It also involves a solid support functionalized with at least one N-hydroxyphthalimide moiety, which is used for protecting the 3′-hydroxy group of a 2′-deoxyribonucleoside during the synthesis of a nucleoside or a derivative thereof. Hollenstein's innovative approach has the potential to enhance the efficiency of nucleoside synthesis.

Career Highlights

Throughout his career, Hollenstein has worked with prominent organizations, including Dna Script and Institut Pasteur. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

One of Hollenstein's notable collaborators is Ivo Sarac. Their partnership has likely fostered advancements in their shared research interests.

Conclusion

Marcel Hollenstein is a distinguished inventor whose work in nucleoside chemistry has led to valuable innovations. His patent and collaborations reflect his commitment to advancing scientific knowledge and technology in this important field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…